Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Form 8.3 - Ergomed plc

24 Oct 2023 15:30

Form 8.3 - Ergomed plc

U.K. DISCLOSURE, Oct. 24, 2023 (GLOBE NEWSWIRE) --

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Identity of the person whose positions/dealings are being disclosed:Glazer Capital LLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficientNA
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeErgomed plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:NA
(e) Date position held/dealing undertaken:October 23, 2023
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1p ordinary
 InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:    
(2) Derivatives (other than options):1,253,7732.46%  
(3) Options and agreements to purchase/sell:    
TOTAL:1,253,7732.46%  

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
    
    
    

(b) Derivatives transactions (other than options)

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
1p ordinaryTotal return swapIncreasing a long position435,77313.40 GBP
     
     
     

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercising

Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:October 24, 2023
Contact name:Ava Lederer
Telephone number:212-808-7306

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
1st Jul 20197:00 amRNSTotal Voting Rights & Block Listing Return
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
19th Jun 20197:00 amRNSShare Options
18th Jun 20193:04 pmRNSBoard Appointment
18th Jun 20192:59 pmRNSResult of AGM
13th Jun 20197:00 amRNSDirector/PDMR Shareholding
10th Jun 20197:00 amRNSPDMR Dealing
4th Jun 20197:00 amRNSAppointment of CFO
3rd Jun 20197:00 amRNSTotal Voting Rights
20th May 20196:30 pmRNSHolding(s) in Company
17th May 20197:00 amRNSNotice of AGM and Annual Report
16th May 20197:01 amRNSHolding(s) in Company
16th May 20197:00 amRNSTrading Update
9th May 201911:15 amRNSHoldings in Company
3rd May 20191:08 pmRNSHolding(s) in Company
23rd Apr 20197:00 amRNSErgomed's PrimeVigilance receives Queen's Award
12th Apr 20197:00 amRNSEarn-Out Shares and PDMR Dealing
10th Apr 20197:00 amRNSPreliminary Results
2nd Apr 20197:00 amRNSNotice of Preliminary Results
1st Apr 20197:00 amRNSRoy Ovel appointed as Chief Commercial Officer
1st Apr 20197:00 amRNSTotal Voting Rights
11th Mar 20191:52 pmRNSChristopher Collins
1st Mar 20197:00 amRNSTotal Voting Rights
13th Feb 20197:00 amRNSProposed Board and Management Changes
1st Feb 201911:31 amRNSExercise of Options & Issue of Equity
31st Jan 20197:00 amRNSErgomed 2018 Trading Update
23rd Jan 20197:00 amRNSBoard and Management Changes
21st Jan 20197:00 amRNSHoldings in Company
4th Jan 201910:34 amRNSDirectors' Dealing
2nd Jan 20197:00 amRNSBlock Listing Six Monthly Return
27th Nov 20181:50 pmRNSHoldings in Company
5th Nov 20182:03 pmRNSHoldings in Company
1st Nov 20182:44 pmRNSErgomed issue of shares
2nd Oct 20182:47 pmRNSBoard Changes
19th Sep 20187:00 amRNSInterim Results
14th Sep 20187:00 amRNSNotice of Interim Results
16th Aug 20184:36 pmRNSHoldings in Company
16th Jul 20185:31 pmRNSChange of auditor
4th Jul 201811:11 amRNSIssue of shares
3rd Jul 20187:00 amRNSAward of share options
2nd Jul 20187:00 amRNSBoard appointment
28th Jun 20187:00 amRNSTrading Update
27th Jun 201811:52 amRNSBlock listing application
21st Jun 20189:11 amRNSExercise of options
15th Jun 20183:14 pmRNSChange of Registered Office
12th Jun 20183:55 pmRNSResults of 2018 Annual General Meeting
25th May 20187:00 amRNSKey hire in pharmacoepidemiology services
24th May 20184:00 pmRNSHolding(s) in Company
21st May 20183:35 pmRNSNotice of AGM
2nd May 20187:00 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.